Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04289038
Other study ID # KA180157
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2021
Est. completion date February 26, 2022

Study information

Verified date February 2022
Source Hacettepe University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The research will be conducted randomly in order to determine the effect of VR and AR on pruritus symptom.


Description:

In this study, there will be three groups: intervention group 1 with autogenic relaxation (AR), intervention group 2 with virtual reality (VR) game application and control group with routine nursing care and kidney functions narration. The number of volunteers to be included in the study was determined by power analysis. Forty patients with itch symptoms will be included in each group. Preliminary application for all three groups will be performed in the patient group registered to the Dialysis Unit of the Nephrology Department of Hacettepe University and Baskent University Hospital. Socio-Demographic Form, 5-D Itch Scale, Dermatology Life Quality Index, State and Trait Anxiety Scale, Pruritus Behavior and SGO / OR Application Log.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date February 26, 2022
Est. primary completion date February 26, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Receiving hemodialysis treatment for the last 6 months, - Receiving four hour hemodialysis treatment three times a week, - 18-65 years of age, - experiencing pruritus for the last month. - Not taking any pharmacological / non-pharmacological treatment for pruritus - No cognitive and psychiatric diagnosis, - Do not use hearing aids, - Open to communication and cooperation, - Using smart mobile phone, - Without liver disease and dermatological diseases, - Patients who agree to participate in the study will be included in the study. Exclusion Criteria: - Pregnant in the research process, - Kidney transplantation, - Experiencing discomfort due to virtual reality glasses, - Patients who voluntarily leave the trial will be excluded from the follow-up.

Study Design


Intervention

Other:
Autogenic Relaxation
Autogenic relaxation
virtual reality game application
virtual reality game application,
kidney function narration
kidney function narration

Locations

Country Name City State
Turkey Nese Altinok Ersoy Ankara Eyalet/Yerleske

Sponsors (2)

Lead Sponsor Collaborator
Hacettepe University Baskent University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary 5-D Itch Scale The score obtained from information about itching severity, frequency, and its effect on daily life activities. Assessing change of 5-D Itch Scale scores baseline, first, fifth and seventh weeks.
Secondary Dermatology Life Quality Index The scale gives an information about quality of life Assessing change of Dermatology Life Quality Index scores baseline, first, fifth and seventh weeks. .
Secondary State-Trait Anxiety Inventory The scale gives an information about anxiety Assessing change of State-Trait Anxiety Inventory scores baseline, first, fifth and seventh weeks.
See also
  Status Clinical Trial Phase
Completed NCT05038982 - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin Phase 2
Completed NCT04510090 - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus Phase 1
Completed NCT02143973 - Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus Phase 2/Phase 3
Terminated NCT01825655 - Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching Phase 4
Completed NCT01236859 - Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus N/A
Completed NCT00782054 - Evaluation of Post Burn Rehabilitation Population for Itch Control Phase 4
Completed NCT04999787 - A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus Phase 2
Recruiting NCT04256759 - Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus Phase 2
Completed NCT04337073 - The Effect of Propofol on Dexamethasone-induced Perineal Pruritus Early Phase 1
Completed NCT04415034 - Scalp Pruritus Measurement Using Visual Analog Scale and 5-d Itch Scale in Children With Pediculosis Capitis
Active, not recruiting NCT05525520 - Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis Phase 2
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Completed NCT04399525 - Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin. N/A
Recruiting NCT02432508 - Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis N/A
Completed NCT02653703 - L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain N/A
Completed NCT01963793 - Topical Aprepitant in Prurigo Patients Phase 2
Completed NCT01232985 - Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults Phase 2
Not yet recruiting NCT00577967 - Gabapentin - A Solution to Uremic Pruritus? N/A
Recruiting NCT06120907 - Swiss Itch Registry
Recruiting NCT04589429 - Adding Nalbuphine for Control of Intrathecal Morphine Pruritus Phase 2